Exagamglogene Autotemcel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted exagamglogene autotemcel, while CIPM (Spain) and HAS (France) did not recommend it.
The record spans 3.3 years, opening at AWMSG (Wales) on 22 Mar 2023 and running to 6 Jul 2026.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 19 of 19 records date from 2023 or later.
6 distinct indication wordings are recorded for exagamglogene autotemcel by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess exagamglogene autotemcel, on 22 Mar 2023; AIFA (Italy) did not open a file until 8 Oct 2025 — a moderate spread of 2.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 11 of 19 dated records fall in 2025 alone.
Restriction is doing real work here: 4 of 15 decisive outcomes narrowed exagamglogene autotemcel to a subgroup rather than accepting or refusing it outright, at G-BA (Germany) and NICE (England).
9 of the 9 agencies here assessed exagamglogene autotemcel more than once, ZIN (Netherlands) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for exagamglogene autotemcel.
The full ledger for exagamglogene autotemcel reads 7 recommended, 4 restricted, 4 not recommended and 2 not assessed, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 25 Feb 2026 | Advies - vergoed exagamglogene autotemcel (Casgevy®) voor de behandeling van ernstige sikkelcelziekte | reimbursed | source |
| CIPM (Spain) | 19 Nov 2025 | Indicaciones terapéuticas autorizadas: β talasemia Casgevy está indicado para el tratamiento de la β-talasemia dependien… | not financed by the SNS · art. 92 d | source |
| AIFA (Italy) | 8 Oct 2025 | Casgevy è indicato per il trattamento della ß talassemia trasfusione dipendente (transfusion dependent ß thalassemia, TD… | fully innovative · reimbursed class H | source |
| G-BA (Germany) | 3 Jul 2025 | Casgevy — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| SMC (Scotland) | 12 May 2025 | For the treatment of transfusion-dependent β-thalassaemia in patients 12 years of age and older for whom haematopoietic stem cell transplantation is appropriate and a hum… | unknown | source |
14 further decisions for exagamglogene autotemcel, across 9 agencies, are not shown here. They include the most recent record on file, 6 Jul 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- lanadelumab — same ATC class B06A — Other hematological agents
- icatibant — same ATC class B06A — Other hematological agents
- berotralstat — same ATC class B06A — Other hematological agents
- garadacimab — same ATC class B06A — Other hematological agents
- conestat alfa — same ATC class B06A — Other hematological agents
- donidalorsen — same ATC class B06A — Other hematological agents
Coverage: 19 decisions for exagamglogene autotemcel from 9 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class B06A — Other hematological agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.